{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:02:28Z","timestamp":1793109748260,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T00:00:00Z","timestamp":1584057600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T00:00:00Z","timestamp":1584057600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CEN Case Rep"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s13730-020-00462-0","type":"journal-article","created":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T07:02:52Z","timestamp":1584082972000},"page":"215-219","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Pembrolizumab-associated nephrotic syndrome recovered from transient hemodialysis in a patient with lung cancer"],"prefix":"10.1007","volume":"9","author":[{"given":"Kento","family":"Ishibuchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takamasa","family":"Iwakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Fukasawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuichi","family":"Furuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,13]]},"reference":[{"key":"462_CR1","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","volume":"33","author":"MA Postow","year":"2015","unstructured":"Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockadeincancertherapy. J Clin Oncol. 2015;33:1974\u201382.","journal-title":"J Clin Oncol"},{"key":"462_CR2","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1159\/000455014","volume":"45","author":"R Wanchoo","year":"2017","unstructured":"Wanchoo R, Karam S, Uppal NN, et al. Adverse renal effects of immune checkpoint inhibitors: a narrative review. Am J Nephrol. 2017;45:160\u20139.","journal-title":"Am J Nephrol"},{"key":"462_CR3","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1186\/s12885-016-2718-y","volume":"16","author":"A Bickel","year":"2016","unstructured":"Bickel A, Koneth I, Enzler-Tschudy A, Neuweiler J, Flatz L, Fr\u00fch M. Pembrolizumab-associated minimal change disease in a patient with malignant pleural mesothelioma. BMC Cancer. 2016;16:656.","journal-title":"BMC Cancer"},{"key":"462_CR4","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1093\/rheumatology\/kew063","volume":"55","author":"RR van den Brom","year":"2016","unstructured":"van den Brom RR, Abdulahad WH, Rutgers A, et al. Rapid granulomatosis with polyangiitis induced by immune checkpoint inhibition. Rheumatology (Oxford). 2016;55:1143\u20135.","journal-title":"Rheumatology (Oxford)"},{"key":"462_CR5","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1053\/j.ajkd.2017.04.026","volume":"70","author":"A Kitchlu","year":"2017","unstructured":"Kitchlu A, Fingrut W, Avila-Casado C, Chan CT, Crump M, Hogg D, Reich HN. Nephrotic syndrome with cancer immunotherapies: a report of 2 cases. Am J Kidney Dis. 2017;70:581\u20135.","journal-title":"Am J Kidney Dis"},{"key":"462_CR6","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1093\/ckj\/sfy100","volume":"12","author":"H Izzedine","year":"2019","unstructured":"Izzedine H, Mathian A, Champiat S, et al. Renal toxicities associated with pembrolizumab. Clin Kidney J. 2019;12:81\u20138.","journal-title":"Clin Kidney J"},{"key":"462_CR7","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1177\/1060028015586218","volume":"49","author":"MS Barbee","year":"2015","unstructured":"Barbee MS, Ogunniyi A, Horvat TZ, Dang TO. Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology. Ann Pharmacother. 2015;49:907\u201337.","journal-title":"Ann Pharmacother"},{"key":"462_CR8","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.18632\/oncotarget.2980","volume":"6","author":"JJ Luke","year":"2015","unstructured":"Luke JJ, Ott PA. PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma. Oncotarget. 2015;6:3479\u201392.","journal-title":"Oncotarget"},{"key":"462_CR9","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1093\/ndt\/gfw467","volume":"32","author":"H Izzedine","year":"2017","unstructured":"Izzedine H, Mateus C, Boutros C, Robert C, Rouvier P, Amoura Z, Mathian A. Renal effects of immune checkpoint inhibitors. Nephrol Dial Transplant. 2017;32:936\u201342.","journal-title":"Nephrol Dial Transplant"},{"issue":"9","key":"462_CR10","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.2169\/internalmedicine.9814-17","volume":"57","author":"S Kishi","year":"2018","unstructured":"Kishi S, Minato M, Saijo A, et al. IgA nephropathy after nivolumab therapy for postoperative recurrence of lung squamous cell carcinoma. Intern Med. 2018;57(9):1259\u201363.","journal-title":"Intern Med"},{"issue":"2","key":"462_CR11","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMc0904283","volume":"361","author":"F Fadel","year":"2009","unstructured":"Fadel F, El Karoui K, Knebelmann B. Anti-CTLA4 antibody-induced lupus nephritis. N Engl J Med. 2009;361(2):211\u20132.","journal-title":"N Engl J Med"},{"issue":"3","key":"462_CR12","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","volume":"90","author":"FB Cortazar","year":"2016","unstructured":"Cortazar FB, Marrone KA, Troxell ML, et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int. 2016;90(3):638\u201347.","journal-title":"Kidney Int"},{"key":"462_CR13","doi-asserted-by":"publisher","first-page":"S1516","DOI":"10.21037\/jtd.2017.12.52","volume":"10","author":"J Remon","year":"2018","unstructured":"Remon J, Mezquita L, Corral J, Vilari\u00f1o N, Reguart N. Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients. J Thorac Dis. 2018;10:S1516\u2013S15331533.","journal-title":"J Thorac Dis"},{"key":"462_CR14","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627\u201339.","journal-title":"N Engl J Med"},{"key":"462_CR15","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123\u201335.","journal-title":"N Engl J Med"},{"key":"462_CR16","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1159\/000186877","volume":"61","author":"A Meyrier","year":"1992","unstructured":"Meyrier A, Delahousse M, Callard P, Rainfray M. Minimal change nephrotic syndrome revealing solid tumors. Nephron. 1992;61:220\u20133.","journal-title":"Nephron"},{"key":"462_CR17","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jaad.2014.02.035","volume":"71","author":"ME Lacouture","year":"2014","unstructured":"Lacouture ME, Wolchok JD, Yosipovitch G, K\u00e4hler KC, Busam KJ, Hauschild A. Ipilimumab in patients with cancer and the management of dermatologic adverse events. J Am Acad Dermatol. 2014;71:161\u20139.","journal-title":"J Am Acad Dermatol"},{"key":"462_CR18","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/ki.2012.180","volume":"82","author":"EC Siddall","year":"2012","unstructured":"Siddall EC, Radhakrishnan J. The pathophysiology of edema formation in the nephrotic syndrome. Kidney Int. 2012;82:635\u201342.","journal-title":"Kidney Int"},{"key":"462_CR19","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/ki.1985.179","volume":"28","author":"B Anton","year":"1985","unstructured":"Anton B, Hendrik A, Jan C, et al. Preservation of blood volume during edema removal in nephrotic subjects. Kidney Int. 1985;28:652\u20137.","journal-title":"Kidney Int"},{"key":"462_CR20","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/cc11454","volume":"17","author":"JA Kellum","year":"2013","unstructured":"Kellum JA, Lameire N. KDIGO AKI guideline work group. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit Care. 2013;17:204.","journal-title":"Crit Care"},{"key":"462_CR21","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40560-018-0308-6","volume":"6","author":"K Doi","year":"2018","unstructured":"Doi K, Nishida O, Shigematsu T, et al. The Japanese clinical practice guideline for acute kidney injury 2016. J Intensive Care. 2018;6:48.","journal-title":"J Intensive Care"},{"key":"462_CR22","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S1081-1206(10)62870-0","volume":"83","author":"A Yuengsrigul","year":"1999","unstructured":"Yuengsrigul A, Chin TW, Nussbaum E. Immunosuppressive and cytotoxic effects of furosemide on human peripheral blood mononuclear cells. Ann Allergy Asthma Immunol. 1999;83:559\u201366.","journal-title":"Ann Allergy Asthma Immunol"}],"container-title":["CEN Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-020-00462-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13730-020-00462-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-020-00462-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,13]],"date-time":"2021-03-13T00:59:44Z","timestamp":1615597184000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13730-020-00462-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,13]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["462"],"URL":"https:\/\/doi.org\/10.1007\/s13730-020-00462-0","relation":{},"ISSN":["2192-4449"],"issn-type":[{"value":"2192-4449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,13]]},"assertion":[{"value":"24 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All the authors declare no competing interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent was obtained from the patient in the case report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}